Wayne, PA – According to filings with the U.S. Securities and Exchange Commission, Ralexar Therapeutics is raising $6,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Pfeiffer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ralexar Therapeutics

Ralexar Therapeutics, Inc., headquartered in Wayne, Pennsylvania, is a privately held specialty pharmaceutical company founded in January of 2014. The company is developing topical and systemic therapies based on Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis.

To learn more about Ralexar Therapeutics, visit http://ralexar.com/

Contact:
David Pfeiffer, Chief Executive Officer
484-318-2988
https://www.linkedin.com/in/dave-pfeiffer-4a123610/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved